I have never seen any reliable evidence for this. CBD, the second most prevalent cannabinoid, acts as a negative allosteric modulator at CB2. There's a weak case that this may decrease cannabis-associated anxiety (because the synthetic JWH-018 was a strong CB2 ligand and caused severe anxiety). CBD is at high doses a DRD2 partial antagonist (antipsychotic effect), but it's very unlikely to reach this level with recreational use. The third-most common cannabinoid is THCV, which acts as an antagonist at the cannabinoid receptors. Beta-caryophyllene, not a cannabinoid, is a very low potency CB2 agonist; it is present in cannabis but also in rosemary, oregano and basil, herbs widely known for their pernicious addictive properties.
THC is a potent CB1 and CB2 partial agonist. It is predominantly responsible for the effects of cannabis. The minor cannabinoids appear, if anything, to reduce the effect of THC.
>I think a lot of people agree that cannabis offers a very favorable ratio of drawbacks and benefits compared to other drugs, including alcohol. Will this still be the case as new formulations are developed?
My only real concern is that dab pens seem to be to joints what smartphones were to the laptop. You used to have to think about what you were doing for a few minutes before inhaling.